Compare ETSY & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETSY | KYMR |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.4B |
| IPO Year | 2015 | 2020 |
| Metric | ETSY | KYMR |
|---|---|---|
| Price | $78.00 | $99.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 26 | 26 |
| Target Price | $62.50 | ★ $107.72 |
| AVG Volume (30 Days) | ★ 3.0M | 768.4K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $441,231,000.00 | $39,211,000.00 |
| Revenue This Year | N/A | $10.61 |
| Revenue Next Year | $3.44 | $8.17 |
| P/E Ratio | $124.82 | ★ N/A |
| Revenue Growth | ★ 20.90 | N/A |
| 52 Week Low | $44.00 | $36.88 |
| 52 Week High | $76.52 | $105.00 |
| Indicator | ETSY | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 75.82 | 74.83 |
| Support Level | $51.56 | $76.40 |
| Resistance Level | N/A | $103.00 |
| Average True Range (ATR) | 2.68 | 4.66 |
| MACD | 0.56 | 2.50 |
| Stochastic Oscillator | 88.89 | 84.32 |
Founded in 2005, Etsy operates a leading global marketplace, connecting roughly 87 million active buyers and 6 million sellers of unique, handmade, and vintage goods. In fiscal 2025, the firm generated $2.9 billion in revenue and almost $12 billion in gross merchandise sales. The firm monetizes its marketplace primarily through transaction fees and advertising, with core categories spanning homeware, jewelry, apparel, and craft supplies. The US drives 74% of sales, though its core geographic reach extends to the UK, Germany, Canada, and Australia.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.